 Stealth BioTherapeutics Corp NASDAQ:MITO has earned a consensus recommendation of Buy from the seven ratings firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage ... 